

Kevin H Mayo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/191077/publications.pdf>

Version: 2024-02-01

126
papers

5,997
citations

66234

42
h-index

82410

72
g-index

129
all docs

129
docs citations

129
times ranked

5577
citing authors

#	ARTICLE	IF	CITATIONS
1	What is the Sugar Code?. ChemBioChem, 2022, 23, .	1.3	20
2	Targeting platelet-derived CXCL12 impedes arterial thrombosis. Blood, 2022, 139, 2691-2705.	0.6	13
3	Comparative study of water-soluble polysaccharides isolated from leaves and roots of Isatis indigotica Fort.. International Journal of Biological Macromolecules, 2022, 206, 642-652.	3.6	10
4	Structure and antioxidant activity of six mushroom-derived heterogalactans. International Journal of Biological Macromolecules, 2022, 209, 1439-1449.	3.6	14
5	Galactofuranose side chains in galactomannans from Penicillium spp. modulate galectin-8-mediated bioactivity. Carbohydrate Polymers, 2022, 292, 119677.	5.1	3
6	Emodin inhibits aggregation of amyloid β peptide 1 α -42 and improves cognitive deficits in Alzheimer's disease transgenic mice. Journal of Neurochemistry, 2021, 157, 1992-2007.	2.1	17
7	Structure \rightarrow function studies of galectin \rightarrow 14, an important effector molecule in embryology. FEBS Journal, 2021, 288, 1041-1055.	2.2	18
8	Targeting the CRD Face of Human Galectin \rightarrow 3 and Allosterically Modulating Glycan Binding by Angiostatic PTX008 and a Structurally Optimized Derivative. ChemMedChem, 2021, 16, 713-723.	1.6	8
9	Topsy-turvy binding of negatively charged homogalacturonan oligosaccharides to galectin-3. Glycobiology, 2021, 31, 341-350.	1.3	7
10	Human galectin-16 has a pseudo ligand binding site and plays a role in regulating c-Rel-mediated lymphocyte activity. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129755.	1.1	17
11	Galectin-3 N-terminal tail prolines modulate cell activity and glycan-mediated oligomerization/phase separation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
12	Actin binding to galectin-13/placental protein-13 occurs independently of the galectin canonical ligand-binding site. Glycobiology, 2021, 31, 1219-1229.	1.3	5
13	Pectic polysaccharides from Radix Sophorae Tonkinensis exhibit significant antioxidant effects. Carbohydrate Polymers, 2021, 262, 117925.	5.1	34
14	Comparative study on the structures of intra- and extra-cellular polysaccharides from Penicillium oxalicum and their inhibitory effects on galectins. International Journal of Biological Macromolecules, 2021, 181, 793-800.	3.6	9
15	Characterizing ligand-induced conformational changes in clinically relevant galectin-1 by HN/H ₂ O (D ₂ O) exchange. Biochimie, 2021, 187, 48-56.	1.3	3
16	Simulating cellular galectin networks by mixing galectins in vitro reveals synergistic activity. Biochemistry and Biophysics Reports, 2021, 28, 101116.	0.7	2
17	The marriage of chemokines and galectins as functional heterodimers. Cellular and Molecular Life Sciences, 2021, 78, 8073-8095.	2.4	13
18	Biochemical Characterization of Two Rhamnogalacturonan Lyases From Bacteroides ovatus ATCC 8483 With Preference for RG-I Substrates. Frontiers in Microbiology, 2021, 12, 799875.	1.5	6

#	ARTICLE	IF	CITATIONS
19	Galectin-13/placental protein 13: redox-active disulfides as switches for regulating structure, function and cellular distribution. <i>Glycobiology</i> , 2020, 30, 120-129.	1.3	11
20	Structural insight into the binding of human galectins to corneal keratan sulfate, its desulfated form and related saccharides. <i>Scientific Reports</i> , 2020, 10, 15708.	1.6	15
21	Co-crystal Structure of <i>Thermosynechococcus elongatus</i> Sucrose Phosphate Synthase With UDP and Sucrose-6-Phosphate Provides Insight Into Its Mechanism of Action Involving an Oxocarbenium Ion and the Glycosidic Bond. <i>Frontiers in Microbiology</i> , 2020, 11, 1050.	1.5	13
22	Injectable hydrogel-loaded nano-hydroxyapatite that improves bone regeneration and alveolar ridge promotion. <i>Materials Science and Engineering C</i> , 2020, 116, 111158.	3.8	51
23	Chemokines and galectins form heterodimers to modulate inflammation. <i>EMBO Reports</i> , 2020, 21, e47852.	2.0	63
24	Pro4 prolyl peptide bond isomerization in human galectin-7 modulates the monomer-dimer equilibrium to affect function. <i>Biochemical Journal</i> , 2020, 477, 3147-3165.	1.7	11
25	A traditional Chinese Medicine, YXQN, Reduces Amyloid-induced Cytotoxicity by Inhibiting A β 242 Aggregation and Fibril Formation. <i>Current Pharmaceutical Design</i> , 2020, 26, 780-789.	0.9	2
26	Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity. <i>Organic Chemistry Frontiers</i> , 2019, 6, 2981-2990.	2.3	4
27	NMR-based insight into galectin-3 binding to endothelial cell adhesion molecule CD146: Evidence for noncanonical interactions with the lectin's CRD β -sandwich F-face. <i>Glycobiology</i> , 2019, 29, 608-618.	1.3	15
28	A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1. <i>Scientific Reports</i> , 2019, 9, 10929.	1.6	23
29	SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability. <i>Cell Communication and Signaling</i> , 2019, 17, 153.	2.7	15
30	Galectin-3 binds selectively to the terminal, non-reducing end of β (1 \rightarrow 4)-galactans, with overall affinity increasing with chain length. <i>Glycobiology</i> , 2019, 29, 74-84.	1.3	12
31	An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature. <i>Vaccine</i> , 2018, 36, 3054-3060.	1.7	21
32	Adhesion/growth-regulatory galectins tested in combination: evidence for formation of hybrids as heterodimers. <i>Biochemical Journal</i> , 2018, 475, 1003-1018.	1.7	32
33	Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 67.	3.5	36
34	Resetting the ligand binding site of placental protein 13/galectin-13 recovers its ability to bind lactose. <i>Bioscience Reports</i> , 2018, 38, .	1.1	10
35	Galectins as Molecular Targets for Therapeutic Intervention. <i>International Journal of Molecular Sciences</i> , 2018, 19, 905.	1.8	83
36	Preparation of individual galactan oligomers, their prebiotic effects, and use in estimating galactan chain length in pectin-derived polysaccharides. <i>Carbohydrate Polymers</i> , 2018, 199, 526-533.	5.1	24

#	ARTICLE	IF	CITATIONS
37	Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	121
38	Novel polysaccharide binding to the N-terminal tail of galectin-3 is likely modulated by proline isomerization. <i>Glycobiology</i> , 2017, 27, 1038-1051.	1.3	19
39	Macromolecular assemblies of complex polysaccharides with galectin-3 and their synergistic effects on function. <i>Biochemical Journal</i> , 2017, 474, 3849-3868.	1.7	37
40	Chemokines from a Structural Perspective. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2088.	1.8	161
41	Probing Functional Heteromeric Chemokine Protein-Protein Interactions through Conformation-Assisted Oxime Ligation. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 14963-14966.	7.2	16
42	Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain. <i>Glycobiology</i> , 2016, 26, 88-99.	1.3	59
43	Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR. <i>Glycobiology</i> , 2016, 26, 888-903.	1.3	66
44	Structural significance of galectin design: impairment of homodimer stability by linker insertion and partial reversion by ligand presence. <i>Protein Engineering, Design and Selection</i> , 2015, 28, 199-210.	1.0	28
45	¹ H, ¹³ C, and ¹⁵ N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-3. <i>Biomolecular NMR Assignments</i> , 2015, 9, 59-63.	0.4	20
46	Defining the Potential of Aglycone Modifications for Affinity/Selectivity Enhancement against Medically Relevant Lectins: Synthesis, Activity Screening, and HSQC-Based NMR Analysis. <i>ChemBioChem</i> , 2015, 16, 126-139.	1.3	16
47	Novel analogs of antitumor agent calixarene O118: Synthesis, cytotoxicity, click labeling with 2-[¹⁸ F]fluoroethylazide, and <i>in vivo</i> evaluation. <i>European Journal of Medicinal Chemistry</i> , 2015, 89, 279-295.	2.6	38
48	Evaluation of ¹¹¹ In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis. <i>Anticancer Research</i> , 2015, 35, 5945-54.	0.5	3
49	Peptides derived from human galectin-3 N-terminal tail interact with its carbohydrate recognition domain in a phosphorylation-dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 126-131.	1.0	24
50	Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. <i>Investigational New Drugs</i> , 2013, 31, 1142-1150.	1.2	44
51	Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with <i>Pseudomonas aeruginosa</i> . <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 3454-3457.	1.1	8
52	Protein lysine N-alkylation and phosphorylation mediated by DTT-generated reactive oxygen species. <i>Protein Science</i> , 2013, 22, 327-346.	3.1	2
53	Structure-Based Optimization of Angiostatic Agent 6DBF7, an Allosteric Antagonist of Galectin-1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 589-599.	1.3	36
54	Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity. <i>Glycobiology</i> , 2013, 23, 508-523.	1.3	42

#	ARTICLE	IF	CITATIONS
55	Structural features for α -galactomannan binding to galectin-1. <i>Glycobiology</i> , 2012, 22, 543-551.	1.3	30
56	Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5121-5129.	2.9	113
57	From Carbohydrate to Peptidomimetic Inhibitors of Galectins. <i>ACS Symposium Series</i> , 2012, , 61-77.	0.5	6
58	¹ H, ¹³ C, and ¹⁵ N backbone and side-chain chemical shift assignments for the 31 kDa human galectin-7 (p53-induced gene 1) homodimer, a pro-apoptotic lectin. <i>Biomolecular NMR Assignments</i> , 2012, 6, 127-129.	0.4	15
59	Synthesis of [¹⁸ F]anginex with high specific activity [¹⁸ F]fluorobenzaldehyde for targeting angiogenic activity in solid tumors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 708-713.	0.5	3
60	Structural aspects of binding of α -linked digalactosides to human galectin-1. <i>Glycobiology</i> , 2011, 21, 1627-1641.	1.3	43
61	Enhancement of T-cell-Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3134-3145.	3.2	64
62	Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. <i>International Journal of Hyperthermia</i> , 2011, 27, 42-52.	1.1	24
63	Inhibiting Tumor Growth by Targeting Tumor Vasculature with Galectin-1 Antagonist Anginex Conjugated to the Cytotoxic Acylfulvene, 6-Hydroxylpropylacylfulvene. <i>Bioconjugate Chemistry</i> , 2010, 21, 20-27.	1.8	40
64	Lactose Binding to Galectin-1 Modulates Structural Dynamics, Increases Conformational Entropy, and Occurs with Apparent Negative Cooperativity. <i>Journal of Molecular Biology</i> , 2010, 397, 1209-1230.	2.0	95
65	Repression of Multiple Myeloma Growth and Preservation of Bone with Combined Radiotherapy and Anti-angiogenic Agent. <i>Radiation Research</i> , 2010, 173, 809-817.	0.7	13
66	The α -galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. <i>Glycobiology</i> , 2009, 19, 1034-1045.	1.3	84
67	Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. <i>Nature Medicine</i> , 2009, 15, 97-103.	15.2	404
68	Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations. <i>Carbohydrate Research</i> , 2009, 344, 1205-1212.	1.1	25
69	The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. <i>Biochemical Journal</i> , 2009, 421, 211-221.	1.7	55
70	¹ H, ¹³ C, and ¹⁵ N backbone and side-chain chemical shift assignments for the 29 kDa human galectin-1 protein dimer. <i>Biomolecular NMR Assignments</i> , 2008, 2, 203-205.	0.4	32
71	Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irifolven. <i>Cancer Letters</i> , 2008, 265, 270-280.	3.2	48
72	CXC and CC Chemokines Form Mixed Heterodimers. <i>Journal of Biological Chemistry</i> , 2008, 283, 24155-24166.	1.6	65

#	ARTICLE	IF	CITATIONS
73	Probing structure-activity relationships in bactericidal peptide $\hat{2}$ pep-25. <i>Biochemical Journal</i> , 2008, 414, 143-150.	1.7	8
74	Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization. <i>Clinical Cancer Research</i> , 2007, 13, 3395-3402.	3.2	270
75	A Journey in Structure-Based Drug Discovery: From Designed Peptides to Protein Surface Topomimetics as Antibiotic and Antiangiogenic Agents. <i>Accounts of Chemical Research</i> , 2007, 40, 1057-1065.	7.6	39
76	Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. <i>International Journal of Clinical Oncology</i> , 2007, 12, 42-47.	1.0	33
77	Topomimetics of Amphipathic $\hat{2}$ -Sheet and Helix-Forming Bactericidal Peptides Neutralize Lipopolysaccharide Endotoxins. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7754-7765.	2.9	56
78	Design of Nonpeptidic Topomimetics of Antiangiogenic Proteins With Antitumor Activities. <i>Journal of the National Cancer Institute</i> , 2006, 98, 932-936.	3.0	102
79	Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications. <i>Cancer Research</i> , 2006, 66, 10770-10777.	0.4	139
80	Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15975-15980.	3.3	424
81	Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. <i>FASEB Journal</i> , 2006, 20, 621-630.	0.2	237
82	Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. <i>International Journal of Cancer</i> , 2005, 115, 312-319.	2.3	81
83	Platelet Factor 4 and Interleukin-8 CXC Chemokine Heterodimer Formation Modulates Function at the Quaternary Structural Level. <i>Journal of Biological Chemistry</i> , 2005, 280, 4948-4958.	1.6	86
84	Measuring protein self-diffusion in protein-protein mixtures using a pulsed gradient spin-echo technique with WATERGATE and isotope filtering. <i>Journal of Magnetic Resonance</i> , 2004, 166, 129-133.	1.2	14
85	Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains. <i>Biochemical Journal</i> , 2004, 378, 93-103.	1.7	75
86	Comparison of ^{13}C and ^{15}N backbone dynamics in protein GB1. <i>Protein Science</i> , 2003, 12, 914-922.	3.1	16
87	^{15}N Backbone Dynamics of Protein GB1: Comparison of Order Parameters and Correlation Times Derived Using Various Model-Free Approaches. <i>Journal of Physical Chemistry B</i> , 2003, 107, 2602-2609.	1.2	22
88	Anti-tumor activity of the novel angiogenesis inhibitor anginex. <i>Cancer Letters</i> , 2003, 194, 55-66.	3.2	65
89	Design of a Partial Peptide Mimetic of Anginex with Antiangiogenic and Anticancer Activity. <i>Journal of Biological Chemistry</i> , 2003, 278, 45746-45752.	1.6	62
90	beta-Sheet is the bioactive conformation of the anti-angiogenic anginex peptide. <i>Biochemical Journal</i> , 2003, 373, 281-288.	1.7	51

#	ARTICLE	IF	CITATIONS
91	Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. <i>Blood</i> , 2003, 101, 4687-4694.	0.6	103
92	The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. <i>Cancer Research</i> , 2003, 63, 382-5.	0.4	85
93	The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. <i>FASEB Journal</i> , 2002, 16, 1991-1993.	0.2	96
94	Residues in Methylosinus trichosporium OB3b Methane Monooxygenase Component B Involved in Molecular Interactions with Reduced- and Oxidized-Hydroxylase Component: A Role for the N-Terminus. <i>Biochemistry</i> , 2001, 40, 9539-9551.	1.2	49
95	Conformational Exchange on the Microsecond Time Scale in α -Helix and β -Hairpin Peptides Measured by ^{13}C NMR Transverse Relaxation. <i>Biochemistry</i> , 2001, 40, 2844-2853.	1.2	18
96	Environmental Scanning Electron Microscopy of the Dehydration of Gel Materials. <i>Microscopy and Microanalysis</i> , 2001, 7, 792-793.	0.2	0
97	Anginex, a designed peptide that inhibits angiogenesis. <i>Biochemical Journal</i> , 2001, 354, 233.	1.7	109
98	Folding of β pep-4 β -sheet sandwich dimers and tetramers is influenced by aliphatic hydrophobic residues at the intersubunit interface. <i>Biochemical Journal</i> , 2001, 357, 739-747.	1.7	5
99	Anginex, a designed peptide that inhibits angiogenesis. <i>Biochemical Journal</i> , 2001, 354, 233-242.	1.7	158
100	Structure-function relationships in novel peptide dodecamers with broad-spectrum bactericidal and endotoxin-neutralizing activities. <i>Biochemical Journal</i> , 2000, 349, 717-728.	1.7	27
101	Internal motional amplitudes and correlated bond rotations in an α -helical peptide derived from ^{13}C and ^{15}N NMR relaxation. <i>Protein Science</i> , 2000, 9, 2118-2127.	3.1	11
102	Heparin Dodecasaccharide Binding to Platelet Factor-4 and Growth-related Protein-4. <i>Journal of Biological Chemistry</i> , 1999, 274, 25317-25329.	1.6	71
103	Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. , 1999, 80, 315-319.		67
104	Using the Model Free Approach to Analyze NMR Relaxation Data in Cases of Anisotropic Molecular Diffusion. <i>Journal of Physical Chemistry B</i> , 1999, 103, 6829-6834.	1.2	22
105	Structure and Dynamics of Peptide Amphiphiles Incorporating Triple-Helical Proteinlike Molecular Architecture. <i>Biochemistry</i> , 1999, 38, 1659-1668.	1.2	115
106	NMR structure and dynamics of monomeric neutrophil-activating peptide 2. <i>Biochemical Journal</i> , 1999, 338, 591-598.	1.7	17
107	A folding pathway for β pep-4 peptide 33mer: From unfolded monomers and β -sheet sandwich dimers to well-structured tetramers. <i>Protein Science</i> , 1998, 7, 358-368.	3.1	26
108	Motional dynamics of residues in a β -hairpin peptide measured by ^{13}C -NMR relaxation. <i>Protein Science</i> , 1998, 7, 720-729.	3.1	18

#	ARTICLE	IF	CITATIONS
109	Designed β -sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1998, 1425, 81-92.	1.1	40
110	NMR Structure of a de Novo Designed, Peptide 33mer with Two Distinct, Compact β -Sheet Folds. <i>Biochemistry</i> , 1997, 36, 5245-5250.	1.2	58
111	A Pulsed-Field Gradient NMR Study of Bovine Pancreatic Trypsin Inhibitor Self-Association. <i>Biochemistry</i> , 1997, 36, 3383-3388.	1.2	63
112	Backbone and side-chain dynamics of residues in a partially folded β -sheet peptide from platelet factor-4. <i>Protein Science</i> , 1997, 6, 355-363.	3.1	16
113	RGD induces conformational transition in purified platelet integrin GPIIb/IIIa-SDS system yielding multiple binding states for fibrinogen β -chain C-terminal peptide. <i>FEBS Letters</i> , 1996, 378, 79-82.	1.3	11
114	NMR and x-ray studies of collagen model peptides. <i>Biopolymers</i> , 1996, 40, 359-370.	1.2	37
115	A recipe for designing water-soluble, β -sheet-forming peptides. <i>Protein Science</i> , 1996, 5, 1301-1315.	3.1	87
116	Stability and Conformational Analysis of Tc-RC160 and Re-RC160: A Experimental and Theoretical Analysis of the Influence of Metal Complexation on the Structural Requisites for Activity. <i>The Journal of Physical Chemistry</i> , 1996, 100, 14630-14636.	2.9	2
117	NMR solution structure of the 32-kDa platelet factor 4 ELR-motif N-terminal chimera: a symmetric tetramer. <i>Biochemistry</i> , 1995, 34, 11399-11409.	1.2	62
118	Quarternary structure amplification of protein folding differences observed in "native" platelet factor-4. <i>FEBS Letters</i> , 1995, 357, 301-304.	1.3	2
119	Alcohol-induced protein folding transitions in platelet factor 4: The O-state. <i>Biochemistry</i> , 1993, 32, 8661-8671.	1.2	10
120	Carbon-13 nuclear magnetic resonance relaxation-derived .psi., .PHI. bond rotational energy barriers and rotational restrictions for glycine ^{13}C .alpha.-methylenes in a GXX-repeat hexadecapeptide. <i>Biochemistry</i> , 1993, 32, 10580-10590.	1.2	31
121	Cell adhesion promoting peptide GVKGDKGNPGWPGAP from the collagen type IV triple helix: cis/trans proline-induced multiple proton NMR conformations and evidence for a KG/PG multiple turn repeat motif in the all-trans proline state. <i>Biochemistry</i> , 1991, 30, 8251-8267.	1.2	57
122	Low-affinity platelet factor 4 proton NMR derived aggregate equilibria indicate a physiologic preference for monomers over dimers and tetramers. <i>Biochemistry</i> , 1991, 30, 925-934.	1.2	28
123	Human platelet factor 4 subunit association/dissociation thermodynamics and kinetics. <i>Biochemistry</i> , 1991, 30, 6402-6411.	1.2	30
124	Human platelet factor 4 monomer-dimer-tetramer equilibria investigated by proton NMR spectroscopy. <i>Biochemistry</i> , 1989, 28, 9469-9478.	1.2	102
125	Understanding Galectin Structure-Function Relationships to Design Effective Antagonists. , 0, , 33-69.		15
126	Determining Methyl-Esterification Patterns in Plant-Derived Homogalacturonan Pectins. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	5